Neste Oil Oyj (0O46)
London Stock Exchange · UK · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 29.96 |
|---|---|
| 52-week range | 15.92 – 35.98 |
| Return, 1 month / 3 months | −12.0% / +0.4% |
| Return, 1 year / 3 years | +64.0% / +0.7% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 36 |
| Volatility (1 year) | 41.5% |
| Worst drawdown (1 year) | -21.2% |
| Average daily value traded | 8.73M EUR |
| Dividend yield | 0.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Neste Oil Oyj is a Finnish refining and marketing company based in Espoo. It refines crude oil into petroleum products such as gasoline, diesel and aviation fuel for transport and industrial customers, and it also produces renewable fuels made from vegetable oils and waste fats. Its renewable diesel and sustainable aviation fuel are supplied to customers in Europe and North America, while its conventional refining serves Baltic and other markets.
Neste Oil Oyj trades under the code 0O46 on the London Stock Exchange in UK, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Neste Oil Oyj (0O46) trades on the London Stock Exchange in UK. It last closed at EUR 29.96 on 27 October 2026.
Its price-based Market X-Ray is 63 out of 100 (a fair price profile), ranking 1,043 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 64.0% and over the last three months it rose 0.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 72 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 7.2% | ||
| From 52-week high | -15.2% | ||
| Momentum | 74 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 0.4% | ||
| 6-month return | 12.0% | ||
| 12-month return, skipping the last month | 86.5% | ||
| Stability (higher is calmer) | 54 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 41.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -21.2% | ||
| Liquidity | 73 · Strong | Trades actively. | |
| Average daily value traded | 8.73M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 25 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.7% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | −2.7% |
|---|---|
| 1 month | −12.0% |
| 3 months | +0.4% |
| 6 months | +12.0% |
| 1 year | +64.0% |
| 3 years | +0.7% |
| 5 years | −30.6% |
Signals
| 50-day / 200-day average | 32.54 / 27.95 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.09 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 26 Mar 2026 | EUR 0.2000 |
| 26 Mar 2025 | EUR 0.2000 |
| 30 Sep 2024 | EUR 0.6000 |
| 28 Mar 2024 | EUR 0.6000 |
| 28 Sep 2023 | EUR 0.5100 |
| 29 Mar 2023 | EUR 0.2500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.